Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1992
10/20/1992US5156960 Microbial process for the production of immunosuppressive antibiotics
10/20/1992US5156957 Transformed mammalian cell containing an expression vector which is capable of producing a heterodimeric human fertility hormone coded by a distinct RNA
10/20/1992US5156949 Immunoassays for antibody to human immunodeficiency virus using recombinant antigens
10/20/1992US5156852 Administering vitamins C and E and zinc, copper, selenium, and manganese compounds
10/20/1992US5156850 Dosage form for time-varying patterns of drug delivery
10/20/1992US5156849 Pharmaceutical composition
10/20/1992US5156847 Aporphinoid alkaloid in nonaqueous solvent
10/20/1992US5156669 Fungicides and plant growth regulators
10/20/1992US5156601 Blend of polyurethane and decyclized poly(N-vinyl lactam)
10/20/1992CA2066395A1 Therapeutical compositions having anti-hiv activity consisting of didesoxy adenosine and substances inhibiting adenosine deaminase
10/20/1992CA2066394A1 Synthetic compounds suitable for the therapy of infections caused by rhinoviruses
10/20/1992CA2066369A1 Control of sex differentiation in fish
10/20/1992CA2066059A1 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds for the treatment of aids
10/20/1992CA1309098C Dihydropyridine derivatives, their preparation and their use
10/20/1992CA1309097C 2-oxo-1-[[(substituted sulfonyl) amino]- carbonyl]azetidines
10/20/1992CA1309095C Aminoimidazoquinoline derivatives
10/20/1992CA1309093C Paf-antagonistic thienotriazolodiazepine compounds and pharmaceutical uses thereof
10/20/1992CA1309088C 17.beta.-(CYCLOPROPYLOXY)ANDROST-5-EN-3.beta.-OL AND RELATED COMPOUNDS USEFUL ASC -- -LYASE INHIBITORS
10/20/1992CA1309087C Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
10/20/1992CA1309045C Fungal antibiotics bu-3608, bu-3608b and bu-3608c
10/20/1992CA1309029C Anesthetic composition and method of using the same
10/20/1992CA1309028C Treating agent for heart failure
10/20/1992CA1309027C Antiasthmatic agent containing imidazoline derivative
10/20/1992CA1309026C Stable 5-fluorouracil compositions
10/20/1992CA1309025C Topical preparation containing ofloxacin
10/20/1992CA1309024C Aqueous pharmaceutical composition containing s-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl -7-oxo-2,3,-dihydro-7h-pyridol[1,2,3,-de][1,4]benzoxazine -6-carboxylic acid
10/20/1992CA1309023C Methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
10/20/1992CA1309022C Method for the preparation of a sustained release pharmaceutical composition and the composition prepared thereby
10/20/1992CA1309021C Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols as percutaneous absorption enhancers
10/19/1992WO1992018522A1 Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
10/19/1992WO1992018502A1 Prodrug esters of phenolic 2-piperidino-1-alkanols
10/19/1992WO1992018129A1 Use of piribedil derivatives and analogues for the treatment of hyperactive or unstable bladders
10/19/1992WO1992018003A1 Inhibitors of kynureninase
10/19/1992CA2108670A1 Inhibitors of kynureninase
10/19/1992CA2108662A1 Use of piribedil derivatives and analogs for the treatment of hyperactive or unstable bladders
10/19/1992CA2108557A1 Prodrug esters of phenolic 2-piperidino-1-alkanols
10/19/1992CA2106386A1 Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
10/19/1992CA2066311A1 (+) and (-) enantiomers of 5-aliphatic-6-(benzoxazinyl- or benzothiazinyl)-2,3,4,5-tetrahydropyridazin-3-ones
10/19/1992CA2066138A1 Semi-synthetic immunosuppressive macrolides
10/19/1992CA2065794A1 Heterocyclic amides
10/18/1992WO1992018546A1 Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
10/18/1992WO1992018498A1 Pyrimidine derivatives for enhancing antitumor activity
10/18/1992CA2108569A1 Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
10/18/1992CA2108561A1 Pyrimidine derivatives for enhancing antitumor activity
10/18/1992CA2064955A1 Amino acid derivatives
10/17/1992WO1992018481A1 Styryl-substituted heteroaryl compounds which inhibit egf receptor tyrosine kinase
10/17/1992WO1992018480A1 1,3,4-trisubstituted piperidine derivatives, their production and use
10/17/1992CA2108367A1 Styryl-substituted heteroaryl compounds which inhibit egf receptor tyrosine kinase
10/17/1992CA2107665A1 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
10/17/1992CA2066132A1 2-phenanthridonyl carbapenems
10/17/1992CA2065962A1 3-aryl oxazolidinone derivatives, a method of preparing them and therapeutic use thereof
10/17/1992CA2065883A1 2-phenanthridonyl carbapenems having cationizeable substituents
10/16/1992WO1992018148A1 An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
10/16/1992WO1992018127A1 Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
10/16/1992WO1992018120A1 Preventive or remedy for ischemia, reperfusion-induced tissue disorder and arrhythmia as well as pulmonary disorder caused by activated oxygen free radical
10/16/1992WO1992018114A1 Nabumetone powders
10/16/1992WO1992018100A1 Antibacterial mild liquid skin cleanser
10/16/1992CA2108480A1 Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
10/16/1992CA2108467A1 An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
10/16/1992CA2108379A1 Nabumetone powders
10/16/1992CA2107001A1 Antibacterial mild liquid surfactant skin cleanser
10/16/1992CA2065985A1 Quinoxalines, processes for their preparation, and their use
10/16/1992CA2065804A1 Hyperpigmentation of skin
10/16/1992CA2065499A1 Indole and dihydroquinoline potassium channel openers
10/16/1992CA2065134A1 Transdermal composition
10/15/1992WO1992017780A1 Method for assaying ionized magnesium and calcium concentrations and a composition of bioavailable magnesium and calcium
10/15/1992WO1992017490A1 Phosphorus containing compounds as inhibitors of retroviruses
10/15/1992WO1992017487A1 5'-phosphatidyl-5-fluorouridine derivative
10/15/1992WO1992017482A1 Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
10/15/1992WO1992017479A1 Antibiotic carbapenem derivatives
10/15/1992WO1992017478A1 5-ALKYL-6-[[AMINO]METHYL]PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF PREPARING AND USING THESE DERIVATIVES
10/15/1992WO1992017475A1 Heterocyclic-cyclic amine derivatives
10/15/1992WO1992017473A1 Crystalline tiagabine hydrochloride monohydrate, its preparation and use
10/15/1992WO1992017469A2 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
10/15/1992WO1992017460A1 Novel compounds
10/15/1992WO1992017453A1 Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
10/15/1992WO1992017445A2 S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
10/15/1992WO1992017211A1 Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
10/15/1992WO1992017210A1 Novel protein polycation conjugates
10/15/1992WO1992017206A1 Wound healing
10/15/1992WO1992017193A1 Medicament containing an agent inhibiting in vivo pathological apoptosis and applications thereof
10/15/1992WO1992017186A1 Compounds that prevent endotoxin shock and method of using the compounds
10/15/1992WO1992017184A2 Bioactive topical siloxane compositions having enhanced performance and safety
10/15/1992WO1992017182A1 Methods and compounds for inhibiting rnase h activity of reverse transcriptase
10/15/1992WO1992017180A1 Topical 5-fluorouracil prodrug composition and method
10/15/1992WO1992017178A1 Remedy for thrombosis and phosphodiesterase inhibitor
10/15/1992WO1992017175A1 Ophthalmic uses of sigma site binders
10/15/1992WO1992017174A1 Process for preparing aqueous suspension
10/15/1992WO1992017172A1 Disubstituted naphthalenes
10/15/1992WO1992017170A1 Novel taurine-based pharmaceutical composition for administration by inhalation
10/15/1992WO1992017169A1 Use of deprenyl to maintain, prevent loss, or recover nerve cell function
10/15/1992WO1992017168A1 Method of preventing nmda receptor-mediated neuronal damage
10/15/1992WO1992017165A1 A single dose vaccination system
10/15/1992WO1992017163A1 Pharmacologically enhanced formulations
10/15/1992WO1992017160A1 Use of sphingolipids in the preparation of a cosmetic or dermapharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
10/15/1992WO1992017065A2 Method of inhibiting fibrosis
10/15/1992WO1992017064A2 Inhibitors of protein kinase c function
10/15/1992WO1992012717A3 A composition containing a tetracycline and use for inhibiting angiogenesis
10/15/1992WO1992012714A3 Food supplement
10/15/1992WO1992011367A3 Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof
1 ... 7240 7241 7242 7243 7244 7245 7246 7247 7248 7249 7250 7251 7252 7253 7254 7255 7256 7257 7258 7259 7260 ... 7860